Fujimoto Minoru

フジモトミノル | Fujimoto Minoru

Affiliation and department：

Research field (1)： Allergies and connective tissue disease

Research theme for competitive and other funds (8)：

2019 - 2022 Application of a new biomarker LRG to real-world clinical practice of inflammatory bowel disease
2017 - 2020 Investigation of the mechanism of LRG, a novel inflammatory molecule, in modulating TGF-beta signaling for the development of therapy in rheumatic diseases
2016 - 2019 Investigation of the clinical significance of a new inflammatory molecule LRG in lupus nephritis
2016 - 2018 Functional analysis of LSR and development of innovative therapy for ovarian cancer stem cells.
2013 - 2016 Proteomic screening for malignant melanoma antigen and development of antibody-based medicine for metastasis.

Show all

Papers (126)：

Minoru Fujimoto, Yuji Hosono, Satoshi Serada, Yuji Suzuki, Tomoharu Ohkawara, Okinori Murata, Ayumi Quick, Katuya Suzuki, Yuko Kaneko, Tsutomu Takeuchi, et al. Leucine-rich α2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis. Modern Rheumatology. 2023
Ryugo Teranishi, Tsuyoshi Takahashi, Yuuki Obata, Toshirou Nishida, Shuichi Ohkubo, Hiromi Kazuno, Yurina Saito, Satoshi Serada, Minoru Fujimoto, Yukinori Kurokawa, et al. Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. International journal of cancer. 2023. 152. 12. 2580-2593
MINORU FUJIMOTO. Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function. International Journal of Cancer. 2023
Mizuki Kanda, Satoshi Serada, Kosuke Hiramatsu, Masashi Funauchi, Kengo Obata, Satoshi Nakagawa, Tomoharu Ohkawara, Okinori Murata, Minoru Fujimoto, Fumiko Chiwaki, et al. Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer. Neoplasia. 2023. 35. 100853-100853
Tsukie Kin Tsukuda, Hiroshi Ohnishi, Minoru Fujimoto, Yu Nakatani, Kazufumi Takamatsu, Tetsuji Naka, Akihito Yokoyama. Lung CCR6-CXCR3- type 2 helper T cells as an indicator of progressive fibrosing interstitial lung diseases. Scientific Reports. 2022. 12. 1. 19577-19577

ｍore...

MISC (195)：

Yuka Shibata, Hideki Nakajima, Kimiko Nakajima, Satoshi Serada, Minoru Fujimoto, Tetsuji Naka, Shigetoshi Sano. Leucine-rich alpha-2 glycoprotein is a predictive marker of therapeutic efficacy of the biologics in psoriatic arthritis. JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY. 2021. 4. 4. 87-89
Biomarkers for inflammatory bowel disease. 2020. 7. 2. 122-127
梶本恵津子, 藤本穣, 松崎慎哉, 遠藤誠之, 世良田聡, 木村正, 仲哲治. 新規炎症マーカーであるLRG(leucine richα2 glycoprotein)の子宮内胎児感染における有用性. 日本臨床免疫学会総会プログラム・抄録集. 2018. 46回. 132-132
飯島英樹, 松岡克善, 新崎信一郎, 世良田聡, 水野慎大, 藤本穰, 金井隆典, 仲哲治. 【Immunology〜領域を超えた挑戦〜】IBD領域炎症性腸疾患の新たなバイオマーカー leucine-rich α2 glycoprotein(LRG)について. クリニシアン. 2018. 65. 10. 940-945
梶本恵津子, 遠藤誠之, 松崎慎哉, 川西陽子, 岡田愛子, 小和貴雄, 田中博子, 柿ヶ野藍子, 味村和哉, 冨松拓治, et al. 新規炎症マーカーであるLRG(leucine rich α2glycoprotein)の子宮内胎児感染における有用性. 日本周産期・新生児医学会雑誌. 2018. 54. 2. 639-639

ｍore...

Patents (12)：

ｍore...

Professional career (1)：

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page